MCID: THY102
MIFTS: 63

Thyroid Cancer, Nonmedullary, 2

Categories: Genetic diseases, Rare diseases, Cancer diseases, Endocrine diseases

Aliases & Classifications for Thyroid Cancer, Nonmedullary, 2

MalaCards integrated aliases for Thyroid Cancer, Nonmedullary, 2:

Name: Thyroid Cancer, Nonmedullary, 2 57
Follicular Thyroid Carcinoma 12 53 29 6 15 73
Thyroid Carcinoma, Follicular 57 76 53 13
Thyroid Cancer, Follicular 53 73
Nmtc2 57 75
Follicular Adenocarcinoma, Well Differentiated 12
Follicular Carcinoma of the Thyroid Gland 12
Thyroid Carcinoma, Follicular, Somatic 57
Cancer, Thyroid, Nonmedullary, Type 2 40
Thyroid Cancer, Non-Medullary, 2 75
Thyroid Follicular Carcinoma 55
Thyroid Gland Adenocarcinoma 73
Adenocarcinoma, Follicular 44
Follicular Adenocarcinoma 12
Follicular Thyroid Cancer 55
Thyroid Adenocarcinoma 12
Follicular Carcinoma 12
Ftc 53

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant


HPO:

32
thyroid cancer, nonmedullary, 2:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 57 188470
Disease Ontology 12 DOID:3962
NCIt 50 C8054
SNOMED-CT via HPO 69 263681008

Summaries for Thyroid Cancer, Nonmedullary, 2

OMIM : 57 Nonmedullary thyroid cancer (NMTC) comprises thyroid cancers of follicular cell origin and accounts for more than 95% of all thyroid cancer cases. The remaining cancers originate from parafollicular cells (medullary thyroid cancer, MTC; 155240). NMTC is classified into 4 groups: papillary, follicular, Hurthle cell (607464), and anaplastic. Approximately 5% of NMTC is hereditary, occurring as a minor component of a familial cancer syndrome (e.g., familial adenomatous polyposis, 175100, Carney complex, 160980) or as a primary feature (familial NMTC or FNMTC). Papillary thyroid cancer (PTC) is the most common histologic subtype of FNMTC, accounting for approximately 85% of cases (summary by Vriens et al., 2009). Follicular thyroid cancer (FTC) accounts for approximately 15% of NMTC and is defined by invasive features that result in infiltration of blood vessels and/or full penetration of the tumor capsule, in the absence of the nuclear alterations that characterize papillary carcinoma. FTC is rarely multifocal and usually does not metastasize to the regional lymph nodes but tends to spread via the bloodstream to the lung and bones. An important histologic variant of FTC is the oncocytic (Hurthle cell, oxyphilic) follicular carcinoma composed of eosinophilic cells replete with mitochondria (summary by Bonora et al., 2010). For a general phenotypic description and a discussion of genetic heterogeneity of NMTC, see NMTC1 (188550). (188470)

MalaCards based summary : Thyroid Cancer, Nonmedullary, 2, also known as follicular thyroid carcinoma, is related to thyroid carcinoma, familial medullary and differentiated thyroid carcinoma. An important gene associated with Thyroid Cancer, Nonmedullary, 2 is SRGAP1 (SLIT-ROBO Rho GTPase Activating Protein 1), and among its related pathways/superpathways are Aldosterone synthesis and secretion and Focal Adhesion. The drugs Salmon Calcitonin and Iodine have been mentioned in the context of this disorder. Affiliated tissues include thyroid, bone and lung, and related phenotypes are abnormality of metabolism/homeostasis and follicular thyroid carcinoma

Disease Ontology : 12 A thyroid carcinoma that has material basis in follicular cells.

UniProtKB/Swiss-Prot : 75 Thyroid cancer, non-medullary, 2: A form of non-medullary thyroid cancer (NMTC), a cancer characterized by tumors originating from the thyroid follicular cells. NMTCs represent approximately 95% of all cases of thyroid cancer and are classified into papillary, follicular, Hurthle cell, and anaplastic neoplasms.

Wikipedia : 76 Follicular thyroid cancer or follicular thyroid carcinoma accounts for 15% of thyroid cancer and occurs... more...

Related Diseases for Thyroid Cancer, Nonmedullary, 2

Diseases in the Thyroid Cancer, Nonmedullary, 2 family:

Thyroid Cancer, Nonmedullary, 1 Thyroid Cancer, Nonmedullary, 3
Thyroid Cancer, Nonmedullary, 4 Thyroid Cancer, Nonmedullary, 5

Diseases related to Thyroid Cancer, Nonmedullary, 2 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 79)
# Related Disease Score Top Affiliating Genes
1 thyroid carcinoma, familial medullary 32.9 CALCA NKX2-1 RET TG
2 differentiated thyroid carcinoma 32.6 BRAF HRAS NKX2-1 NRAS PAX8 PPARG
3 thyroiditis 31.6 CALCA RET TG THRB TSHR
4 thyroid cancer, nonmedullary, 1 31.2 BRAF LGALS3 NKX2-1 PAX8 RET TG
5 follicular adenoma 30.1 CALCA LGALS3 NKX2-1 PAX8 PTEN RET
6 familial papillary or follicular thyroid carcinoma 12.1
7 trabecular follicular adenocarcinoma 12.1
8 papillary follicular thyroid adenocarcinoma 11.9
9 tumoral calcinosis, hyperphosphatemic, familial, 1 11.5
10 giant congenital nevus 11.2 HRAS NRAS
11 ovarian melanoma 11.1 HRAS NRAS PTEN
12 mucoepidermoid thyroid carcinoma 11.1 CALCA TG
13 acral lentiginous melanoma 11.1 BRAF NRAS PTEN
14 thyroid carcinoma, hurthle cell 11.1
15 schimmelpenning-feuerstein-mims syndrome 11.0 HRAS NRAS
16 chromosome 14q11-q22 deletion syndrome 11.0 HRAS NKX2-1
17 ovarian serous cystadenocarcinoma 11.0 BRAF HRAS NRAS
18 neonatal hypothyroidism 11.0 PAX8 TG TSHR
19 suppurative thyroiditis 11.0 CALCA TG
20 endemic goiter 11.0 CALCA TG TSHR
21 suppression of tumorigenicity 12 11.0 BRAF HRAS PTEN
22 melanoma, cutaneous malignant 1 11.0 HRAS NRAS PTEN
23 nontoxic goiter 11.0 CALCA TG TSHR
24 giant cell glioblastoma 11.0 BRAF PPARG PTEN
25 ovarian germ cell cancer 11.0 NKX2-1 RET TG
26 thyroid sarcoma 11.0 CALCA TG
27 toxic diffuse goiter 11.0 DIO2 TG TSHR
28 clivus chordoma 11.0 HRAS PTEN
29 skin melanoma 11.0 BRAF HRAS NRAS PTEN
30 ovarian cystic teratoma 11.0 CALCA NKX2-1 TG
31 water-clear cell adenoma 11.0 PAX8 TG
32 respiratory system cancer 10.9 HRAS NKX2-1 PTEN
33 cell type cancer 10.9 HRAS NKX2-1 NRAS PTEN
34 ovarian germ cell teratoma 10.9 NKX2-1 NRAS RET TG
35 small cell carcinoma 10.9 CALCA NKX2-1 PTEN
36 parathyroid carcinoma 10.9 CALCA LGALS3 RET
37 pilocytic astrocytoma 10.9 BRAF HRAS KDR PTEN
38 cowden disease 10.9 CALCA PTEN RET TG
39 brain cancer 10.9 BRAF HRAS NRAS PTEN
40 tumoral calcinosis, hyperphosphatemic, familial, 2 10.9
41 tumoral calcinosis, hyperphosphatemic, familial, 3 10.9
42 hyperthyroidism 10.9 TG THRB TSHR
43 spitz nevus 10.9 BRAF HRAS
44 mixed type thymoma 10.9 PAX8 PTEN
45 graves disease 1 10.9 DIO2 TG THRB TSHR
46 athyreosis 10.9 NKX2-1 PAX8 TG TSHR
47 atypical follicular adenoma 10.9 CALCA TG
48 benign struma ovarii 10.9 HRAS NRAS RET TG TSHR
49 renal cell carcinoma, papillary, 1 10.9 BRAF HRAS NRAS PAX8 PTEN
50 squamous cell carcinoma, head and neck 10.9 BRAF HRAS MIR197 PTEN

Graphical network of the top 20 diseases related to Thyroid Cancer, Nonmedullary, 2:



Diseases related to Thyroid Cancer, Nonmedullary, 2

Symptoms & Phenotypes for Thyroid Cancer, Nonmedullary, 2

Symptoms via clinical synopsis from OMIM:

57
Neoplasia:
nonmedullary thyroid carcinoma (papillary and follicular)


Clinical features from OMIM:

188470

Human phenotypes related to Thyroid Cancer, Nonmedullary, 2:

32
# Description HPO Frequency HPO Source Accession
1 abnormality of metabolism/homeostasis 32 HP:0001939
2 follicular thyroid carcinoma 32 HP:0006731
3 non-medullary thyroid carcinoma 32 HP:0040198

GenomeRNAi Phenotypes related to Thyroid Cancer, Nonmedullary, 2 according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.03 HRAS
2 Decreased viability GR00221-A-1 10.03 RET HRAS KDR NRAS PPARG
3 Decreased viability GR00221-A-2 10.03 RET HRAS KDR PPARG
4 Decreased viability GR00221-A-3 10.03 HRAS KDR NRAS PPARG
5 Decreased viability GR00221-A-4 10.03 PPARG RET KDR
6 Decreased viability GR00231-A 10.03 RET
7 Decreased viability GR00301-A 10.03 RET
8 Decreased viability GR00402-S-2 10.03 RET HRAS KDR NRAS PPARG
9 Reduced mammosphere formation GR00396-S 9.17 BRAF HRAS KDR NRAS PAX8 PPARG

MGI Mouse Phenotypes related to Thyroid Cancer, Nonmedullary, 2:

46 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.34 TSHR BRAF HRAS KDR LGALS3 NKX2-1
2 homeostasis/metabolism MP:0005376 10.32 HRAS KDR LGALS3 NKX2-1 NRAS PAX8
3 growth/size/body region MP:0005378 10.31 BRAF DIO2 HRAS KDR NKX2-1 NRAS
4 cardiovascular system MP:0005385 10.29 PAX8 PPARG PTEN RET THRB BRAF
5 endocrine/exocrine gland MP:0005379 10.29 BRAF DIO2 HRAS NKX2-1 NRAS PAX8
6 cellular MP:0005384 10.28 LGALS3 NKX2-1 NRAS PAX8 PPARG PTEN
7 nervous system MP:0003631 10.21 BRAF HRAS KDR LGALS3 NKX2-1 PAX8
8 digestive/alimentary MP:0005381 10.18 BRAF DIO2 HRAS LGALS3 NKX2-1 NRAS
9 neoplasm MP:0002006 10.16 BRAF HRAS LGALS3 NKX2-1 NRAS PPARG
10 normal MP:0002873 10.07 BRAF HRAS KDR MINPP1 NKX2-1 NRAS
11 no phenotypic analysis MP:0003012 10.01 THRB HRAS KDR NKX2-1 NRAS PAX8
12 renal/urinary system MP:0005367 9.92 BRAF DIO2 HRAS LGALS3 PAX8 PPARG
13 reproductive system MP:0005389 9.91 BRAF LGALS3 NKX2-1 PAX8 PPARG PTEN
14 respiratory system MP:0005388 9.76 BRAF HRAS KDR LGALS3 NKX2-1 PTEN
15 skeleton MP:0005390 9.73 PAX8 PPARG PTEN THRB TSHR BRAF
16 vision/eye MP:0005391 9.23 BRAF KDR NRAS PAX8 PPARG PTEN

Drugs & Therapeutics for Thyroid Cancer, Nonmedullary, 2

Drugs for Thyroid Cancer, Nonmedullary, 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 131)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Salmon Calcitonin Approved, Investigational Phase 3,Phase 2 47931-85-1 16129616
2
Iodine Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 7553-56-2 807
3
Calcitonin gene-related peptide Investigational Phase 3,Phase 2 83652-28-2
4 Anti-Infective Agents Phase 2, Phase 3,Phase 1,Not Applicable
5 Bone Density Conservation Agents Phase 3,Phase 2
6 calcitonin Phase 3,Phase 2
7 Hormones Phase 3,Phase 2,Phase 1
8 Anti-Infective Agents, Local Phase 2, Phase 3,Phase 1,Not Applicable
9 cadexomer iodine Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
10 Micronutrients Phase 2, Phase 3,Phase 1,Not Applicable
11 Trace Elements Phase 2, Phase 3,Phase 1,Not Applicable
12 Hormone Antagonists Phase 3,Phase 2
13 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2
14
Rosiglitazone Approved, Investigational Phase 2,Phase 1 122320-73-4 77999
15
Everolimus Approved Phase 2 159351-69-6 6442177
16
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
17
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
18
Indinavir Approved Phase 2 150378-17-9 5362440
19
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
20
Azacitidine Approved, Investigational Phase 2,Phase 1 320-67-2 9444
21
Decitabine Approved, Investigational Phase 2 2353-33-5 451668
22
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
23
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
24
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
25
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
26
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
27
Gefitinib Approved, Investigational Phase 2,Not Applicable 184475-35-2 123631
28
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4
29
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
30
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
31
Tamoxifen Approved Phase 2 10540-29-1 2733526
32
Lenvatinib Approved, Investigational Phase 2 417716-92-8
33
Pembrolizumab Approved Phase 2 1374853-91-4
34
Trametinib Approved Phase 2 871700-17-3 11707110
35
Lenalidomide Approved Phase 2,Phase 1 191732-72-6 216326
36
Dabrafenib Approved, Investigational Phase 2 1195765-45-7 44462760 44516822
37
Irinotecan Approved, Investigational Phase 1, Phase 2 97682-44-5, 100286-90-6 60838
38
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
39
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
40
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
41
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
42
Nicotinamide Approved, Investigational, Nutraceutical Phase 2 98-92-0 936
43
Maleic acid Experimental Phase 2,Phase 1 110-16-7 444266
44
Doxil Approved June 1999 Phase 2 31703
45
Camptothecin Experimental Phase 1, Phase 2 7689-03-4
46
Cediranib Investigational Phase 1, Phase 2 288383-20-0 9933475
47 Hypoglycemic Agents Phase 2,Phase 1
48 Anti-Bacterial Agents Phase 2,Phase 1
49 Antibiotics, Antitubercular Phase 2
50 Antifungal Agents Phase 2

Interventional clinical trials:

(show top 50) (show all 56)
# Name Status NCT ID Phase Drugs
1 A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen. Completed NCT00295763 Phase 3 Thyrogen (thyrotropin alfa for injection)
2 IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients Recruiting NCT01398085 Phase 2, Phase 3
3 Iodine I 131 With or Without Thyroid-Stimulating Hormone in Treating Patients Who Have Undergone Surgery for Thyroid Cancer Active, not recruiting NCT00415233 Phase 3
4 Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer Unknown status NCT00098852 Phase 2 rosiglitazone maleate
5 Everolimus in Treating Patients With Progressive or Recurrent, Unresectable, or Metastatic Thyroid Cancer Unknown status NCT01118065 Phase 2 everolimus
6 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
7 Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131 Completed NCT00085293 Phase 2 Decitabine
8 Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy Completed NCT00104871 Phase 2 Bortezomib
9 Thalidomide in Treating Patients With Thyroid Cancer Completed NCT00026533 Phase 2 thalidomide
10 Effect of Lithium Carbonate on Low-Dose Radioiodine Therapy in Early Thyroid Cancer Completed NCT00251316 Phase 2 Lithium Carbonate;Placebo
11 Sutent Adjunctive Treatment of Differentiated Thyroid Cancer Completed NCT00668811 Phase 2 SU011248, Sutent
12 Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine Completed NCT00098813 Phase 2 romidepsin
13 Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer Completed NCT00118248 Phase 2 tanespimycin
14 Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy Completed NCT00729157 Phase 2
15 Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer Completed NCT01811212 Phase 2 Cabozantinib S-malate
16 Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer Completed NCT00519896 Phase 2 sunitinib malate
17 Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer Completed NCT00134043 Phase 2 vorinostat
18 Celecoxib in Treating Patients With Progressive Metastatic Differentiated Thyroid Cancer Completed NCT00061906 Phase 2 celecoxib
19 Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy Completed NCT00095836 Phase 2 Gefitinib
20 Everolimus in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer Completed NCT01164176 Phase 2 everolimus
21 A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer Completed NCT00121628 Phase 2 AMG 706
22 Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors Completed NCT00019331 Phase 2 DetoxPC
23 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
24 Lenvatinib and Pembrolizumab in DTC Recruiting NCT02973997 Phase 2 Lenvatinib
25 Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer Recruiting NCT02393690 Phase 2 Selumetinib
26 Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer Recruiting NCT02152995 Phase 2 Trametinib
27 REVLIMID® (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary and Follicular Thyroid Carcinomas Active, not recruiting NCT00287287 Phase 2 Lenalidomide
28 Efficacy and Safety of Vandetanib (ZD6474) in Patients With Metastatic Papillary or Follicular Thyroid Cancer Active, not recruiting NCT00537095 Phase 2 Vandetanib
29 Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer Active, not recruiting NCT01723202 Phase 2 dabrafenib;trametinib
30 Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers Active, not recruiting NCT01631552 Phase 1, Phase 2 IMMU-132
31 Sunitinib in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery Active, not recruiting NCT00381641 Phase 2 Sunitinib Malate
32 Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer Active, not recruiting NCT01208051 Phase 1, Phase 2 Cediranib Maleate;Lenalidomide
33 Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer Not yet recruiting NCT03506048 Phase 2 Lenvatinib
34 Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer Terminated NCT00095693 Phase 2 sorafenib tosylate
35 A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors Completed NCT01100619 Phase 1 rosiglitazone;XL184
36 Azacitidine to Restore Thyroid Function in Patients With Persistent or Metastatic Thyroid Cancer Completed NCT00004062 Phase 1 azacitidine;liothyronine sodium
37 Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery Completed NCT01413113 Phase 1 pazopanib hydrochloride
38 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Completed NCT00004074 Phase 1
39 Boronophenylalanine-Fructose Complex (BPA-F) and/or Sodium Borocaptate (BSH) Followed By Surgery in Treating Patients With Thyroid Cancer, Head and Neck Cancer, or Liver Metastases Completed NCT00062348 Phase 1 boronophenylalanine-fructose complex;sodium borocaptate
40 Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer Completed NCT00005842 Phase 1 tipifarnib
41 NGR-TNF in Treating Patients With Advanced Solid Tumors Completed NCT00098943 Phase 1
42 SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and Neck Completed NCT00005647 Phase 1 paclitaxel;semaxanib
43 Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer Active, not recruiting NCT00470496 Phase 1 HPPH;photodynamic therapy
44 S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors Withdrawn NCT00937417 Phase 1 docetaxel;vandetanib
45 Biomarkers to Distinguish Benign From Malignant Thyroid Neoplasm Completed NCT01433809
46 Pre-Operative Nodal Staging of Thyroid Cancer Using USPIO MRI: Preliminary Study Completed NCT01927887 Not Applicable Ferumoxytol
47 Testicular Function After Iodine 131 Therapy in Papillary Carcinoma Patients Completed NCT01150318 Not Applicable Administration of 131 iodine
48 Metabolic Effects of Synthetic Thyroid Hormone for Thyroid Cancer Treatment Completed NCT01441154
49 Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer Completed NCT00068497 Not Applicable gefitinib
50 Iodine I 131 in Treating Patients With Thyroid Cancer Completed NCT00416949 Not Applicable

Search NIH Clinical Center for Thyroid Cancer, Nonmedullary, 2

Cochrane evidence based reviews: adenocarcinoma, follicular

Genetic Tests for Thyroid Cancer, Nonmedullary, 2

Genetic tests related to Thyroid Cancer, Nonmedullary, 2:

# Genetic test Affiliating Genes
1 Follicular Thyroid Carcinoma 29 HRAS MINPP1 NRAS PTEN SRGAP1

Anatomical Context for Thyroid Cancer, Nonmedullary, 2

MalaCards organs/tissues related to Thyroid Cancer, Nonmedullary, 2:

41
Thyroid, Bone, Lung, Lymph Node, Liver, Brain, Endothelial

Publications for Thyroid Cancer, Nonmedullary, 2

Articles related to Thyroid Cancer, Nonmedullary, 2:

(show top 50) (show all 360)
# Title Authors Year
1
Synchronous and Metastatic Papillary and Follicular Thyroid Carcinomas with Unique Molecular Signatures. ( 28710706 )
2018
2
Tumour growth rate of follicular thyroid carcinoma is not different from that of follicular adenoma. ( 29509975 )
2018
3
A six-gene panel to label follicular adenoma, low- and high-risk follicular thyroid carcinoma. ( 29298844 )
2018
4
An upper cervical cord compression secondary to occult follicular thyroid carcinoma metastases successfully treated with multiple radioiodine therapies: A clinical case report. ( 29019888 )
2017
5
miR-146a and miR-146b promote proliferation, migration and invasion of follicular thyroid carcinoma via inhibition of ST8SIA4. ( 28427206 )
2017
6
A case of metastatic follicular thyroid carcinoma complicated with Graves' disease after total thyroidectomy. ( 28883260 )
2017
7
PVALB diminishes [Ca2+] and alters mitochondrial features in follicular thyroid carcinoma cells through AKT/GSK3I^ pathway. ( 27458244 )
2016
8
Follicular thyroid carcinoma in a male adolescent with Williams-Beuren syndrome. ( 27116698 )
2016
9
ST6GalNAcII mediates tumor invasion through PI3K/Akt/NF-I_B signaling pathway in follicular thyroid carcinoma. ( 26820593 )
2016
10
miR-4299 mediates the invasive properties and tumorigenicity of human follicular thyroid carcinoma by targeting ST6GALNAC4. ( 26715099 )
2016
11
Follicular thyroid carcinoma but not adenoma recruits tumor-associated macrophages by releasing CCL15. ( 26875556 )
2016
12
Photoallergic reaction in a patient receiving vandetanib for metastatic follicular thyroid carcinoma: a case report. ( 25886034 )
2015
13
Low frequency of PAX8-PPARI^ rearrangement in follicular thyroid carcinomas in Japanese patients. ( 25708358 )
2015
14
The impact of CLAUDIN-1 on follicular thyroid carcinoma aggressiveness. ( 26219679 )
2015
15
Missed Initial Diagnosis of Malignant Struma Ovarii Containing Follicular Thyroid Carcinoma: Metastatic Pulmonary Recurrence 17 yr After Ovariectomy. ( 26262453 )
2015
16
Metastatic follicular thyroid carcinoma masquerading as olfactory neuroblastoma: with skull-base, cranium, paranasal sinus, lung, and diffuse bone metastases. ( 25569410 )
2015
17
Follicular thyroid carcinoma with skull metastases. ( 25797278 )
2015
18
Difference between papillary and follicular thyroid carcinoma outcomes: an experience from Egyptian institution. ( 25859412 )
2015
19
Follicular thyroid carcinoma in patient followed for Graves' disease. An exceptional eventuality. ( 27126433 )
2015
20
The Diagnostic Usefulness of HMGA2, Survivin, CEACAM6, and SFN/14-3-3 I' in Follicular Thyroid Carcinoma. ( 25812733 )
2015
21
Role of GPER1, EGFR and CXCR1 in differentiating between malignant follicular thyroid carcinoma and benign follicular thyroid adenoma. ( 26617848 )
2015
22
Iodophilic synchronous phalangeal and choroidal metastasis from follicular thyroid carcinoma: a case report and review. ( 25114878 )
2014
23
FDG PET/CT in the detection of pancreatic metastasis in a patient with follicular thyroid carcinoma and negative I-131 whole body scan findings. ( 25224195 )
2014
24
Prognostic factors of follicular thyroid carcinoma. ( 25156926 )
2014
25
Follicular thyroid carcinoma with distant metastasis: outcome and prognostic factor. ( 24420337 )
2014
26
Clinical significance of integrin I^6 as a tumor recurrence factor in follicular thyroid carcinoma. ( 24844802 )
2014
27
Differential miRNA expression defines migration and reduced apoptosis in follicular thyroid carcinomas. ( 24631480 )
2014
28
Spinal cord compression as initial presentation of metastatic occult follicular thyroid carcinoma. ( 24966555 )
2014
29
Clinicopathological and prognostic analysis of follicular thyroid carcinoma in a single institute over a 15-year period. ( 24613740 )
2014
30
Follicular thyroid carcinoma presenting as a soft tissue thigh mass. ( 24703053 )
2014
31
Follicular thyroid carcinoma characterized by abundant stromal components with chondroid and osseous metaplasia in a dog. ( 24805905 )
2014
32
A rare case of solitary subcutaneous scalp metastasis from follicular thyroid carcinoma revealed with positron emission tomography/computed tomography: a case report and review. ( 25022416 )
2014
33
Clear cell variant of follicular thyroid carcinoma with normal thyroid-stimulating hormone value: a case report. ( 24884725 )
2014
34
An uncommon presentation of follicular thyroid carcinoma: when chronic back pain should raise a flag. ( 25470908 )
2014
35
NRAS codon 61 mutation is associated with distant metastasis in patients with follicular thyroid carcinoma. ( 24820091 )
2014
36
Metastatic Follicular Thyroid Carcinoma Secreting Thyroid Hormone and Radioiodine Avid without Stimulation: A Case Report and Literature Review. ( 25400957 )
2014
37
Notable decrease of malignant pleural effusion after treatment with sorafenib in radioiodine-refractory follicular thyroid carcinoma. ( 24684401 )
2014
38
False-positive uptake of 124I in a laryngeal cyst mimicking thyroid remnant after thyroidectomy and 131i therapy for follicular thyroid carcinoma. ( 24561682 )
2014
39
Actual incidence and clinical behaviour of follicular thyroid carcinoma: an institutional experience. ( 24741369 )
2014
40
An uncommon presentation of follicular thyroid carcinoma: when chronic back pain should raise a flag. ( 25508535 )
2014
41
Follicular thyroid carcinoma metastasis to the internal jugular vein demonstrated by 131I SPECT/CT. ( 24566419 )
2014
42
Multidisciplinary approach to follicular thyroid carcinoma with giant mandibular and multiple sites metastases Case report. ( 25712423 )
2014
43
Metastatic follicular thyroid carcinoma to the body of the mandible mimicking an odontogenic tumor. ( 23771388 )
2013
44
Distant metastasis at diagnosis and large tumor size are significant prognostic factors of widely invasive follicular thyroid carcinoma. ( 23358100 )
2013
45
Comparison with published systems of a new staging system for papillary and follicular thyroid carcinoma. ( 23106409 )
2013
46
Prognostic factors of minimally invasive follicular thyroid carcinoma: extensive vascular invasion significantly affects patient prognosis. ( 23327839 )
2013
47
Follicular thyroid carcinoma with signet ring cell morphology: fine-needle aspiration cytology, histopathology, and immunohistochemistry. ( 24068558 )
2013
48
Floating left innominate vein neoplastic thrombus: A rare case of mediastinal extension of follicular thyroid carcinoma. ( 24335091 )
2013
49
Skeletal muscle metastasis as an initial presentation of follicular thyroid carcinoma: a case report and a review of the literature. ( 23607000 )
2013
50
Molecular photoacoustic imaging of follicular thyroid carcinoma. ( 23349314 )
2013

Variations for Thyroid Cancer, Nonmedullary, 2

UniProtKB/Swiss-Prot genetic disease variations for Thyroid Cancer, Nonmedullary, 2:

75
# Symbol AA change Variation ID SNP ID
1 HRAS p.Gln61Lys VAR_045979 rs28933406
2 MINPP1 p.Ser41Leu VAR_022836 rs119486096
3 MINPP1 p.Gln270Arg VAR_022837 rs104894171
4 NRAS p.Gln61Arg VAR_006847 rs11554290
5 SRGAP1 p.Gln149His VAR_075879 rs781626187
6 SRGAP1 p.Ala275Thr VAR_075880 rs797044990
7 SRGAP1 p.Arg617Cys VAR_075882 rs114817817
8 SRGAP1 p.His875Arg VAR_075883 rs61754221

ClinVar genetic disease variations for Thyroid Cancer, Nonmedullary, 2:

6
(show all 16)
# Gene Variation Type Significance SNP ID Assembly Location
1 MINPP1 NM_004897.4(MINPP1): c.122C> T (p.Ser41Leu) single nucleotide variant Pathogenic rs119486096 GRCh37 Chromosome 10, 89264794: 89264794
2 MINPP1 NM_004897.4(MINPP1): c.122C> T (p.Ser41Leu) single nucleotide variant Pathogenic rs119486096 GRCh38 Chromosome 10, 87505037: 87505037
3 MINPP1 NM_004897.4(MINPP1): c.809A> G (p.Gln270Arg) single nucleotide variant Pathogenic rs104894171 GRCh37 Chromosome 10, 89268264: 89268264
4 MINPP1 NM_004897.4(MINPP1): c.809A> G (p.Gln270Arg) single nucleotide variant Pathogenic rs104894171 GRCh38 Chromosome 10, 87508507: 87508507
5 HRAS NM_005343.3(HRAS): c.181C> A (p.Gln61Lys) single nucleotide variant Likely pathogenic rs28933406 GRCh37 Chromosome 11, 533875: 533875
6 HRAS NM_005343.3(HRAS): c.181C> A (p.Gln61Lys) single nucleotide variant Likely pathogenic rs28933406 GRCh38 Chromosome 11, 533875: 533875
7 NRAS NM_002524.4(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
8 NRAS NM_002524.4(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic rs11554290 GRCh38 Chromosome 1, 114713908: 114713908
9 BRAF NM_004333.4(BRAF): c.1801A> G (p.Lys601Glu) single nucleotide variant Pathogenic rs121913364 GRCh37 Chromosome 7, 140453134: 140453134
10 BRAF NM_004333.4(BRAF): c.1801A> G (p.Lys601Glu) single nucleotide variant Pathogenic rs121913364 GRCh38 Chromosome 7, 140753334: 140753334
11 SRGAP1 NM_020762.3(SRGAP1): c.447A> C (p.Gln149His) single nucleotide variant Pathogenic rs781626187 GRCh38 Chromosome 12, 64016970: 64016970
12 SRGAP1 NM_020762.3(SRGAP1): c.447A> C (p.Gln149His) single nucleotide variant Pathogenic rs781626187 GRCh37 Chromosome 12, 64410750: 64410750
13 SRGAP1 NM_020762.3(SRGAP1): c.823G> A (p.Ala275Thr) single nucleotide variant Pathogenic rs797044990 GRCh37 Chromosome 12, 64456718: 64456718
14 SRGAP1 NM_020762.3(SRGAP1): c.823G> A (p.Ala275Thr) single nucleotide variant Pathogenic rs797044990 GRCh38 Chromosome 12, 64062938: 64062938
15 SRGAP1 NM_020762.3(SRGAP1): c.1849C> T (p.Arg617Cys) single nucleotide variant risk factor rs114817817 GRCh37 Chromosome 12, 64502747: 64502747
16 SRGAP1 NM_020762.3(SRGAP1): c.1849C> T (p.Arg617Cys) single nucleotide variant risk factor rs114817817 GRCh38 Chromosome 12, 64108967: 64108967

Cosmic variations for Thyroid Cancer, Nonmedullary, 2:

9
(show top 50) (show all 337)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM26419 TSHR thyroid,NS,carcinoma,follicular carcinoma c.1897G>T p.D633Y 14:81143955-81143955 32
2 COSM26455 TSHR thyroid,NS,carcinoma,follicular carcinoma c.1891T>A p.F631I 14:81143949-81143949 32
3 COSM26485 TSHR thyroid,NS,carcinoma,follicular carcinoma c.1894A>G p.T632A 14:81143952-81143952 32
4 COSM26418 TSHR thyroid,NS,carcinoma,follicular carcinoma c.1895C>T p.T632I 14:81143953-81143953 32
5 COSM26450 TSHR thyroid,NS,carcinoma,follicular carcinoma c.1456A>T p.I486F 14:81143514-81143514 32
6 COSM10656 TP53 thyroid,NS,carcinoma,follicular carcinoma c.742C>T p.R248W 17:7674221-7674221 32
7 COSM43624 TP53 thyroid,NS,carcinoma,follicular carcinoma c.875A>G p.K292R 17:7673745-7673745 32
8 COSM6943090 STAG2 thyroid,NS,carcinoma,follicular carcinoma c.1100T>G p.F367C 23:124051203-124051203 32
9 COSM5546625 SMAD4 thyroid,NS,carcinoma,follicular carcinoma c.767A>T p.Q256L 18:51058224-51058224 32
10 COSM5880107 SMAD4 thyroid,NS,carcinoma,follicular carcinoma c.1060G>C p.V354L 18:51065527-51065527 32
11 COSM1570338 RET thyroid,NS,carcinoma,follicular carcinoma c.2651A>T p.E884V 10:43120124-43120124 32
12 COSM5546623 RB1 thyroid,NS,carcinoma,follicular carcinoma c.2039T>C p.I680T 13:48459766-48459766 32
13 COSM23654 PTEN thyroid,NS,carcinoma,follicular carcinoma c.701G>A p.R234Q 10:87957919-87957919 32
14 COSM23650 PTEN thyroid,NS,carcinoma,follicular carcinoma c.728T>C p.F243S 10:87957946-87957946 32
15 COSM5224 PTEN thyroid,NS,carcinoma,follicular carcinoma c.370T>A p.C124S 10:87933129-87933129 32
16 COSM23652 PTEN thyroid,NS,carcinoma,follicular carcinoma c.496G>A p.V166I 10:87952121-87952121 32
17 COSM5033 PTEN thyroid,NS,carcinoma,follicular carcinoma c.389G>A p.R130Q 10:87933148-87933148 32
18 COSM23653 PTEN thyroid,NS,carcinoma,follicular carcinoma c.476G>A p.R159K 10:87933235-87933235 32
19 COSM23651 PTEN thyroid,NS,carcinoma,follicular carcinoma c.353A>G p.H118R 10:87933112-87933112 32
20 COSM760 PIK3CA thyroid,NS,carcinoma,follicular carcinoma c.1624G>A p.E542K 3:179218294-179218294 32
21 COSM29096 PIK3CA thyroid,NS,carcinoma,follicular carcinoma c.1558G>A p.D520N 3:179218228-179218228 32
22 COSM28544 PIK3CA thyroid,NS,carcinoma,follicular carcinoma c.3026G>A p.G1009E 3:179234183-179234183 32
23 COSM33601 PIK3CA thyroid,NS,carcinoma,follicular carcinoma c.3155C>T p.T1052I 3:179234312-179234312 32
24 COSM33599 PIK3CA thyroid,NS,carcinoma,follicular carcinoma c.3052G>A p.D1018N 3:179234209-179234209 32
25 COSM33598 PIK3CA thyroid,NS,carcinoma,follicular carcinoma c.3002T>A p.L1001H 3:179234159-179234159 32
26 COSM33600 PIK3CA thyroid,NS,carcinoma,follicular carcinoma c.3046T>C p.F1016L 3:179234203-179234203 32
27 COSM12458 PIK3CA thyroid,NS,carcinoma,follicular carcinoma c.1634A>C p.E545A 3:179218304-179218304 32
28 COSM29095 PIK3CA thyroid,NS,carcinoma,follicular carcinoma c.3001C>A p.L1001I 3:179234158-179234158 32
29 COSM29097 PIK3CA thyroid,NS,carcinoma,follicular carcinoma c.1649T>C p.F550S 3:179218319-179218319 32
30 COSM28547 PIK3CA thyroid,NS,carcinoma,follicular carcinoma c.3180C>T p.H1060H 3:179234337-179234337 32
31 COSM564 NRAS thyroid,NS,carcinoma,follicular carcinoma c.35G>A p.G12D 1:114716126-114716126 32
32 COSM707 MET thyroid,NS,carcinoma,follicular carcinoma c.3029C>T p.T1010I 7:116771936-116771936 32
33 COSM517 KRAS thyroid,NS,carcinoma,follicular carcinoma c.34G>A p.G12S 12:25245351-25245351 32
34 COSM532 KRAS thyroid,NS,carcinoma,follicular carcinoma c.38G>A p.G13D 12:25245347-25245347 32
35 COSM516 KRAS thyroid,NS,carcinoma,follicular carcinoma c.34G>T p.G12C 12:25245351-25245351 32
36 COSM522 KRAS thyroid,NS,carcinoma,follicular carcinoma c.35G>C p.G12A 12:25245350-25245350 32
37 COSM518 KRAS thyroid,NS,carcinoma,follicular carcinoma c.34G>C p.G12R 12:25245351-25245351 32
38 COSM551 KRAS thyroid,NS,carcinoma,follicular carcinoma c.182A>C p.Q61P 12:25227342-25227342 32
39 COSM96532 IDH1 thyroid,NS,carcinoma,follicular carcinoma c.390A>G p.I130M 2:208248393-208248393 32
40 COSM96533 IDH1 thyroid,NS,carcinoma,follicular carcinoma c.399T>A p.H133Q 2:208248384-208248384 32
41 COSM498 HRAS thyroid,NS,carcinoma,follicular carcinoma c.182A>T p.Q61L 11:533874-533874 32
42 COSM500 HRAS thyroid,NS,carcinoma,follicular carcinoma c.182A>C p.Q61P 11:533874-533874 32
43 COSM28618 GNAS thyroid,NS,carcinoma,follicular carcinoma c.679C>A p.Q227K 20:58909540-58909540 32
44 COSM27900 GNAS thyroid,NS,carcinoma,follicular carcinoma c.681G>T p.Q227H 20:58909542-58909542 32
45 COSM27895 GNAS thyroid,NS,carcinoma,follicular carcinoma c.602G>A p.R201H 20:58909366-58909366 32
46 COSM6932694 EIF1AX thyroid,NS,carcinoma,follicular carcinoma c.338-2A>G p.? 23:20130609-20130609 32
47 COSM3372212 EIF1AX thyroid,NS,carcinoma,follicular carcinoma c.338-1G>C p.? 23:20130608-20130608 32
48 COSM1203589 DICER1 thyroid,NS,carcinoma,follicular carcinoma c.5437G>C p.E1813Q 14:95091293-95091293 32
49 COSM13224 CDKN2A thyroid,NS,carcinoma,follicular carcinoma c.242C>T p.P81L 9:21971117-21971117 32
50 COSM4420757 CDH1 thyroid,NS,carcinoma,follicular carcinoma c.1108G>A p.D370N 16:68812234-68812234 32

Expression for Thyroid Cancer, Nonmedullary, 2

Search GEO for disease gene expression data for Thyroid Cancer, Nonmedullary, 2.

Pathways for Thyroid Cancer, Nonmedullary, 2

Pathways related to Thyroid Cancer, Nonmedullary, 2 according to GeneCards Suite gene sharing:

(show all 27)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.92 BRAF HRAS NRAS PAX8 TG TSHR
2
Show member pathways
12.8 BRAF HRAS KDR NRAS PTEN
3
Show member pathways
12.68 BRAF HRAS KDR NRAS PTEN
4
Show member pathways
12.61 BRAF HRAS NRAS PAX8 PPARG PTEN
5 12.52 BRAF HRAS NRAS PAX8 PPARG PTEN
6
Show member pathways
12.34 BRAF HRAS KDR NRAS PTEN
7
Show member pathways
12.3 BRAF HRAS NRAS PTEN
8 12.2 BRAF HRAS KDR NRAS
9
Show member pathways
12.12 HRAS KDR NRAS PTEN
10
Show member pathways
12.08 BRAF HRAS NRAS PPARG
11 12.06 HRAS KDR NRAS PTEN
12
Show member pathways
12.04 BRAF HRAS NRAS PPARG
13
Show member pathways
11.95 BRAF HRAS NRAS PTEN
14 11.82 DIO2 HRAS NRAS THRB
15 11.75 BRAF HRAS NRAS PTEN
16 11.65 BRAF HRAS NRAS
17
Show member pathways
11.59 BRAF HRAS NRAS
18 11.53 BRAF HRAS NRAS
19 11.48 HRAS NRAS PTEN RET
20 11.4 HRAS NRAS RET
21
Show member pathways
11.27 BRAF HRAS KDR NRAS RET
22 11.2 BRAF HRAS NRAS
23 11.09 HRAS NRAS PTEN
24 11.08 BRAF HRAS KDR NRAS
25 10.85 BRAF HRAS MIR197 PAX8 TSHR
26 10.74 HRAS NRAS
27 10.34 TG TSHR

GO Terms for Thyroid Cancer, Nonmedullary, 2

Biological processes related to Thyroid Cancer, Nonmedullary, 2 according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 cell differentiation GO:0030154 9.95 BRAF KDR LGALS3 PAX8 PPARG RET
2 MAPK cascade GO:0000165 9.84 BRAF HRAS NRAS RET
3 positive regulation of gene expression GO:0010628 9.83 BRAF HRAS NKX2-1 PTEN RET
4 axon guidance GO:0007411 9.8 HRAS NKX2-1 NRAS RET
5 animal organ morphogenesis GO:0009887 9.56 BRAF HRAS NKX2-1 THRB
6 hormone-mediated signaling pathway GO:0009755 9.54 PPARG THRB TSHR
7 hormone biosynthetic process GO:0042446 9.52 DIO2 TG
8 thyroid hormone metabolic process GO:0042403 9.51 DIO2 TG
9 cellular response to nerve growth factor stimulus GO:1990090 9.5 BRAF CALCA PTEN
10 regulation of axon regeneration GO:0048679 9.46 BRAF PTEN
11 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.35 BRAF HRAS KDR PTEN RET
12 thyroid-stimulating hormone signaling pathway GO:0038194 9.16 PAX8 TSHR
13 thyroid gland development GO:0030878 9.02 BRAF NKX2-1 PAX8 TG THRB
14 signal transduction GO:0007165 10.13 BRAF HRAS NRAS PPARG RET SRGAP1

Molecular functions related to Thyroid Cancer, Nonmedullary, 2 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 MAP kinase kinase kinase activity GO:0004709 9.43 BRAF KDR RET
2 mitogen-activated protein kinase kinase binding GO:0031434 9.33 BRAF KDR RET
3 thyroid-stimulating hormone receptor activity GO:0004996 8.96 PAX8 TSHR
4 inositol-1,3,4,5-tetrakisphosphate 3-phosphatase activity GO:0051717 8.62 MINPP1 PTEN

Sources for Thyroid Cancer, Nonmedullary, 2

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....